CELDARA MEDICAL, LLC

Basic Information

16 CAVENDISH CT, CENTERRA RESOURCE PARK, DRTC
LEBANON, NH, 03766-1441

http://celdaramedical.com

Company Profile

n/a

Additional Details

Field Value
DUNS: 828763263
Hubzone Owned: N
Socially and Economically Disadvantaged: N
Woman Owned: N
Number of Employees: 11


  1. Destroying the HIV-1 provirus by utilizing components of the CRISPR/Cas system

    Amount: $451,598.00

    DESCRIPTION (provided by applicant): The goal of this project is to develop a plasmid-based therapy that will destroy the integrated HIV-1 DNA (HIV- 1 provirus) in infected cells. Current HIV-1 anti-r ...

    SBIR Phase I 2014 Department of Health and Human Services
  2. Dampening CAR therapy-induced cytokine storm with anti-GM-CSF antibodies

    Amount: $224,985.00

    DESCRIPTION (provided by applicant): The long-term aim of this project is to reduce or eliminate the serious adverse events associated with cellular immunotherapy used to treat cancer. The current imp ...

    SBIR Phase I 2014 Department of Health and Human Services
  3. Therapy of transplantation-induced oxidative injury using polymeric antioxidants

    Amount: $225,000.00

    DESCRIPTION (provided by applicant): Ischemia-reperfusion (I/R) injury during renal transplantation surgery is responsible for oxidative stresses which result in immune activation and graft rejection. ...

    SBIR Phase I 2014 Department of Health and Human Services
  4. PHASE I, SBIR CONTRACT, N43TR-14-001,?MUTIPLEXED BIOMARKER ASSAY FOR CLASSIFICATION OF PATIENTS?.

    Amount: $223,419.00

    Not Available

    SBIR Phase I 2014 Department of Health and Human Services
  5. Gene Expression Signatures to Predict Treatment Response in Systemic Sclerosis

    Amount: $1,494,019.00

    DESCRIPTION (provided by applicant): Today, systemic sclerosis (SSc) clinical trials generally include all subsets; some may benefit, others do not, confounding measures of efficacy. Because each expr ...

    SBIR Phase II 2014 Department of Health and Human Services
  6. Combination immunotherapies for the treatment of melanoma

    Amount: $288,300.00

    DESCRIPTION (provided by applicant): Melanoma is the most common form of cancer in young adults1, and its incidence is rising at a rate higher than any of the seven most common cancers2, increasing 45 ...

    SBIR Phase I 2013 Department of Health and Human Services
  7. Depletion of Dendritic Cells by Immunotoxin as Therapy for Myocardial Infarction

    Amount: $2,068,342.00

    DESCRIPTION (provided by applicant): MI is the leading cause of death in the developed world, including the United States. In 2005 over 8.1 million Americans had an MI; 30% died before reaching hospit ...

    SBIR Phase II 2012 Department of Health and Human Services
  8. ChNKG2D-Targeted Cellular Cancer Therapy: Phase I Clinical Trial

    Amount: $3,219,451.00

    DESCRIPTION (provided by applicant): The global burden of cancer doubled between 1975 and 2000. Cancer became the leading cause of death worldwide in 2010, and is projected to double again by 2020 an ...

    SBIR Phase II 2012 Department of Health and Human Services
  9. Preclinical Development of a Novel Plaque-Regressing Therapy For Atherosclerosis

    Amount: $675,944.00

    DESCRIPTION (provided by applicant): Cardiovascular disease (CVD) is the leading cause of death in the world. The staggering mortality rate is expected to increase significantly in the next ten years ...

    SBIR Phase I 2012 Department of Health and Human Services
  10. Scleroderma Subtyping from Fresh and Archived Biopsies using NextGen Sequencing

    Amount: $535,368.00

    DESCRIPTION (provided by applicant): Systemic sclerosis (SSc) is an autoimmune disease that presents with a heterogeneous and complex phenotype. Major manifestations of the disease are skin fibrosis, ...

    SBIR Phase I 2011 Department of Health and Human Services

Agency Micro-sites

US Flag An Official Website of the United States Government